Anti-Human IL 12/23 (Briakinumab) Dylight® 488

Pricing & Details

Product No.LT511
Clone
ABT-874
Protein
IL-12/IL-23 p40
Formats AvailableView All
Product Type
Biosimilar Recombinant Human Monoclonal Antibody
Alternate Names
IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23
Isotype
Human IgG1λ
Applications
FA
,
FC
,
IF
Prod No.
Size
Price
Avail.
Qty
Add to cart
LT511-100 μg
100 µg
$325.00
Made to Order
Max:
Min: 1
Step: 1

Antibody Details

Product Details

Reactivity Species
Human
Host Species
Human
Expression Host
HEK-293
FC Effector Activity
Active
Immunogen
This antibody was produced by phage display technology.
Product Concentration
0.2 mg/ml
Formulation
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage and Handling
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Regulatory Status
Research Use Only (RUO). Non-Therapeutic.
Country of Origin
USA
Excitation Laser
Blue Laser (493 nm)
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
FA
Additional Reported Applications For Relevant Conjugates ?
B
N
WB
ELISA
IP
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
Antigen Distribution
IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.
Background
Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Antigen Details

NCBI Gene Bank ID

References & Citations

1. Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123
Flow Cytometry

Formats Available

Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Cookie Policy
Leinco Technologies uses cookies to improve your experience and our website service. By continuing to browse our website, you accept our cookie policy.